Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab Meeting Abstract
| Authors: | Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; Sha, F.; Von Keudell, G.; Straus, D. J.; Noy, A.; Younes, A.; Hamlin, P. A.; Brentjens, R. J.; Tejedor-Alonso, M. A.; Horwitz, S. M.; Zelenetz, A. D. |
| Abstract Title: | Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 431s |
| Language: | English |
| ACCESSION: | WOS:000560368303282 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.8062 |
| Notes: | Meeting Abstract: 8062 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
